With reference to disclosures dated May 31, 2023 and July 12, 2023 regarding the signing of definitive agreements to acquire additional stake of 7.24% (on fully diluted basis) in Immunoadoptive Cell Therapy Private Limited (lmmunoACT), an advanced cell and gene therapy company for a cash consideration of Rs 80 Crores and update on payment of Tranche1 subscription amount to ImmunoACT respectively, Laurus Labs has informed that the Company has paid the subscription amount of Rs 32,00,75,184 (Rupees Thirty Two Crores Seventy Five Thousand One Hundred and Eighty Four only) as ‘Tranche 2 (Final) Subscription Amount’. The Shareholding of the Company in ImmunoACT is 33.86% (on a fully-diluted basis).
The above information is a part of company’s filings submitted to BSE.
